Marathon Asset Management
-
Malvern’s Baudax Bio Closes $50 Million Loan Deal to Officially Launch Its Non-Opioid Pain Med
Malvern-based Baudax Bio has signed a loan deal with Marathon Asset Management worth $50 million to support the launch of its intravenous and non-opioid pain…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
